• Kiora Pharmaceuticals licensed South Korea ophthalmic development, regulatory, and commercialization rights for KIO-301 to Chong Kun Dang Pharmaceutical.
• Deal includes a USD 1 million upfront payment, development and regulatory milestones, royalties on future KIO-301 sales in South Korea.
• Chong Kun Dang will run local development and commercialization, coordinating with Théa and Senju on a single global Phase 3 trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiora Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608190700NEWSFILECNPR____20260819_310396_1) on August 19, 2026, and is solely responsible for the information contained therein.